logo

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Paul Andrew Hyslop

This inventor holds 4 USPTO granted patents and 2 published patent applications. Top assignees: Scios Inc., Eli Lilly and Company, Other. Active years: 2002-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Andrew Hyslop. Retrieved from https://idiyas.com/inventor/paul-andrew-hyslop

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 100.0

Average Co-Inventor Count = 7.8

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:

goldMedal2 out of 82 
 
Scios Inc.
 patents
silverMedal1 out of 4,517 
 
Eli Lilly and Company
 patents
bronzeMedal2 out of 834,570 
Other
 patents
where one patent can have more than one assignee

Years Active: 2002-2006

Loading Chart...
4 patents (USPTO):Explore Patents
1. 7087399 - β-secretase and modulation of β-secretase activity (2006-08-08),
2. 7033812 - β-secretase and modulation of β-secretase activity (2006-04-25),
3. 6596474 - Prevention and treatment of amyloid-associated disorders (2003-07-22),
4. 6486350 - Biological reagents and methods for determining the mechanism in the generation of &bgr;-amyloid peptide (2002-11-26),

Title: Paul Andrew Hyslop: Innovator in Neurological Research

Introduction

Paul Andrew Hyslop is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of neurological research, particularly in the study of Alzheimer's disease. With a total of four patents to his name, Hyslop's work focuses on innovative methods and compounds that could lead to breakthroughs in treatment.

Latest Patents

Hyslop's latest patents include a novel β-secretase and methods for modulating β-secretase activity. This invention concerns a method of partially purifying this novel β-secretase and its application in assays to screen for potential drug candidates against Alzheimer's disease and other neurological disorders. The novel β-secretase has an estimated molecular weight of about 32-39 kDa or 22-26 kDa in HEK293 cell membrane extracts and human brain samples, respectively. This was calculated from radiation inactivation analysis, and it has a pH optimum at about pH 6.5-7.0.

Career Highlights

Throughout his career, Hyslop has worked with various companies, including Scios Inc. His experience in the industry has allowed him to develop and refine his innovative ideas, contributing to advancements in medical research.

Collaborations

Hyslop has collaborated with notable coworkers such as Barbara Cordell and Ziyang Zhong. These partnerships have played a crucial role in the development of his inventions and research.

Conclusion

Paul Andrew Hyslop is a distinguished inventor whose work in neurological research has the potential to impact the treatment of Alzheimer's disease significantly. His innovative patents and collaborations highlight his commitment to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…